Anti-GCNT3 antibody produced in rabbit，100UL，HPA011154-100UL，Sigma

General description

GCNT3 (glucosaminyl (N-acetyl) transferase 3, mucin type) is the mucin type member of core 2 β-1,6-N-acetylglucosaminyltransferase (C2GnT) family, which has three members. This gene is located on human chromosome 15q21.3, spans ~8.26kb, and has two introns and three exons. It is predominantly expressed in mucous-secreting tissues, such as small and large intestines, trachea, and stomach as well as thyroid. It is also expressed in pancreas, kidney and colon. It is a type II transmembrane protein.

Immunogen

Glucosaminyl(N-acetyl) transferase 3, mucin type recombinant protein epitope signature tag (PrEST)

Application

Anti-GCNT3 antibody produced in rabbit, a Prestige Antibody, is developed and validated by the Human Protein Atlas (HPA) project . Each antibody is tested by immunohistochemistry against hundreds of normal and disease tissues. These images can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. The antibodies are also tested using immunofluorescence and western blotting. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.

Biochem/physiol Actions

GCNT3 (glucosaminyl (N-acetyl) transferase 3, mucin type) is responsible for the production of the three β6GlcNAc branches on secreted mucins. Not only does it catalyze the synthesis of core 2 branches, it also catalyzes the synthesis of core 4 and 1 branches. Its expression is suppressed by epidermal growth factor, and enhanced by all-trans retinoic acid and T helper 2 (Th2) cytokines such as IL-13. These cis-regulatory elements, therefore, have potential as therapeutic targets for disorders with mucus hyper-secretion. GCNT3 is responsible for the modification of O-glycans and integrin signaling, which in turn affect cell adhesion and migration and tumorigenesis. This gene is under-expressed in majority of colorectal cancer patients. It has potential to determine the relapse risk in early stage colon cancer patients, and might also help to determine the response to chemotherapy in the same.

Features and Benefits

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Physical form

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Other Notes

Corresponding Antigen APREST72004

Legal Information

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.